Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study


Conference Paper

Summary: To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82 %, with 66 patients (7 %) reporting serious adverse events and 19 patients (2 %) reporting fractures.

Full Text

Duke Authors

Cited Authors

  • Silverman, SL; Siris, E; Kendler, DL; Belazi, D; Brown, JP; Gold, DT; Lewiecki, EM; Papaioannou, A; Simonelli, C; Ferreira, I; Balasubramanian, A; Dakin, P; Ho, P; Siddhanti, S; Stolshek, B; Recknor, C

Published Date

  • September 19, 2014

Published In

Published By

Electronic International Standard Serial Number (EISSN)

  • 1433-2965

International Standard Serial Number (ISSN)

  • 0937-941X

Digital Object Identifier (DOI)

  • 10.1007/s00198-014-2871-6

Citation Source

  • Scopus